## 2D Data Matrix to be printed with serial number on each leaflet. The number should not be repeated

-- DOSAGE FORMS AND STRENGTHS


To report SUSPECTED ADVERSE REACTIONS, contact Hetero Labs Limited at 1-866-495-1995 or FDA at 1-800-FDA-1088 or

DRUG INTERACTIONS
 See FPI for drugs that may interfere with systemic exposure and reduce mycophenolate mofetil efficacy: antacids with magnesium or aluminum hydroxide, proton pump inhibitors, drugs that interfere with enterohepatic recirculation, the proton pump inhibitors are always and the proton pump inhibitors.

telmisartan, calcium-free phosphate binders. (7.1) mycophenolate modetil may reduce effectiveness of oral contraceptives. Use of additional barrier contraceptive methods is

USE IN SPECIFIC POPULATIONS
 Male Patients: Sexually active male patients and/or their female partners are recommended to use effective contraception during treatment of the male patient and for at least 90 days after cessation of treatment (8.3)

## Note: Position of the pharma code and product name will change as per the folding machine feasibility



Revised: 07/2024

### HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use MYCOPHENOLATE MOFETIL CAPSULES safely and effectively. See full prescribing information for MYCOPHENOLATE MOFETIL CAPSULES MYCOPHENOLATE MOFETIL capsules, for oral use Initial U.S. Approval: 1995	Capsules: 250 mg     CONTRAINDICATIONS     Hypersensitivity to mycophenolate mofetil, mycophenolic acid or any component of the drug product (4)     WARNINGS AND PRECAUTIONS     Blood Dyscrasias (Neutropenia, Red Blood Cell Aplasia): Monitor with blood tests; consider treatment interruption or dose
WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES and SERIOUS INFECTIONS See full prescribing information for complete boxed warning	reduction. (5.4) • Gastrointestinal Complications: Monitor for complications such as bleeding, ulceration and perforations, particularly in
<ul> <li>Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Avoid if safer treatment options are available. Females of reproductive potential must be counseled regarding pregnancy prevention and planning <i>Isee Warnings and Precautions</i> (5.1).</li> <li>Increased risk of development of lymphoma and other malignancies, particularly of the skin <i>[see Warnings and Precautions (5.2)]</i>.</li> <li>Increased susceptibility to infections, including opportunistic infections and severe infections with fatal outcomes <i>[see Warnings and Precautions (5.3)]</i>.</li> </ul>	<ul> <li>patients with underlying gastrointestinal disorders. (5.5)</li> <li>Hypoxanthine-Guanine Phosphoribosyl-Transferase Deficiency: Avoid use of mycophenolate mofetil. (5.6)</li> <li>Acute Inflammatory Syndrome Associated with Mycophenolate Products: Monitor for this paradoxical inflammatory reaction. (5.7)</li> <li>Immunizations: Avoid live attenuated vaccines. (5.8)</li> <li>Blood Donation: Avoid during therapy and for 6 weeks thereafter. (5.11)</li> <li>Semen Donation: Avoid during therapy and for 90 days thereafter. (5.12)</li> <li>Potential Impairment on Driving and Use of Machinery: Mycophenolate mofetil may affect ability to drive or operate</li> </ul>
INDICATIONS AND USAGE	Potential impairment on briving and use of Machinery. Mycophenolate index may anect ability to drive of operate machinery. (5.14)

ADULTS	DOSAGE
Kidney Transplant	1 g twice daily (2.2)
<u>Heart Transplant</u>	1.5 g twice daily orally (2.3)
Liver Transplant	1.5 g twice daily orally (2.4)
PEDIATRICS	
Kidney Transplant	600 mg/m <sup>2</sup> orally twice daily, up to maximum of 2 g daily (2.2)
<u>Heart Transplant</u>	600 mg/m² orally twice daily (starting dose) up to a maximum of 900 mg/m² twice daily (3 g) (2.3)
Liver Transplant	600 mg/m <sup>2</sup> orally twice daily (starting dose) up to a maximum of 900 mg/m <sup>2</sup> twice daily (3 g) (2.4)

Mycophenolate mofetil Intravenous is an alternative when patients cannot tolerate oral medication. Administer within 24

hours following transplantation, until patients can tolerate oral medication, up to 14 days. (2.1)

Reduce or interrupt dosing in the event of neutropenia. (2.5) See full prescribing information (EPI) for: adjustments for renal in

<ul> <li>Reduce of interrupt dosing in the event of r</li> </ul>	ieutropenia. (2.3)
<ul> <li>See full prescribing information (FPI) for: a</li> </ul>	djustments for renal impairment and neutropenia. (2.5)

EIIII DDECCD	IRING INFORM	ATION: CONTEN	* 21

WAR	NING: EMBRYOFETAL TOXICITY	, MALIGNANCIES	and SERIOUS	INFECTIONS

DOSAGE AND ADMINISTRATION

- Important Administration Instructions
- 2.1 2.2 Dosage Recommendations for Kidney Transplant Patients
- 2.3
- Dosage Recommendations for Heart Transplant Patients Dosage Recommendations for Liver Transplant Patients
- Dosage Modifications: Patients with Renal Impairment, Neutropenia 2.5
- DOSAGE FORMS AND STRENGTHS
- CONTRAINDICATIONS
- WARNINGS AND PRECAUTIONS 5.1 Embryofetal Toxicity
- 5.2 Lymphoma and Other Malignancies
- Serious Infections Blood Dyscrasias: Neutropenia and Pure Red Cell Aplasia (PRCA) 5.3 5.4
- 5.5 Gastrointestinal Complications
- Patients with Hypoxanthine-Guanine Phosphoribosyl-Transferase Deficiency (HGPRT) Acute Inflammatory Syndrome Associated with Mycophenolate Products 5.6 5.7
- 5.8 Immunizations
- 5.11 Blood Donation 5.12 Semen Donation
- 5.13 Effect of Concomitant Medications on Mycophenolic Acid Concentrations 5.14 Potential Impairment of Ability to Drive or Operate Machinery
- ADVERSE REACTIONS
- 6.1 Clinical Trials Experience 6.2 Postmarketing Experience
- DRUG INTERACTIONS
- Effect of Other Drugs on Mycophenolate Mofetil Effect of Mycophenolate Mofetil on Other Drugs
- 8 USE IN SPECIFIC POPULATIONS
- Pregnancy
- 8.2 Lactatio
- Females and Males of Reproductive Potential 8.3 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Patients with Renal Impairment8.7 Patients with Hepatic Impairment

### FULL PRESCRIBING INFORMATION

### WARNING: EMBRYOFETAL TOXICITY, MALIGNANCIES and SERIOUS INFECTIONS

- Use during pregnancy is associated with increased risks of first trimester pregnancy loss and congenital malformations. Avoid if safer treatment options are available. Females of reproductive potential must be counseled regarding pregnancy prevention and planning *(see Warnings and Precautions (5.1), Use in Special Populations (8.1, e a)*
- Increased risk of development of lymphoma and other malignancies, particularly of the skin [see Warnings and Precautions (5.2)].
- Increased susceptibility to bacterial, viral, fungal and protozoal infections, including opportunistic infections and viral reactivity of hepatitis B and C, which may lead to hospitalizations and fatal outcomes [see Warnings and Precautions (5.3)].
- INDICATIONS AND USAGE
- Mycophenolate mofetil capsules are indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney [see Clinical Studies (14.1)], heart [see Clinical Studies (14.2)] or liver transplants [see Clinical Studies (14.3)], in combination with other immunosuppressants.

### DOSAGE AND ADMINISTRATION

Important Administration Instructions cophenolate mofetil should not be used without the supervision of a physician with experience in immun

- 10 OVERDOSAGE DESCRIPTION CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 14.1 Kidney Transplantatior 14.2 Heart Transplantation
- 14.3 Liver Transplantation REFERENCES HOW SUPPLIED/STORAGE AND HANDLING
   16.1 Handling and Disposal
   16.2 Mycophenolate Mofetil Capsules 250 mg

www.fda.gov/medwatch.com

nmended. (7.2)

• See FPI for other important drug interactions. (7)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide

- 17 PATIENT COUNSELING INFORMATION
- Embryofetal Toxicity 17.1 Embryotetal Toxicity
  17.2 Development of Lymphoma and Other Malignancies
- 17.3 Increased Risk of Serious Infections17.4 Blood Dyscrasias17.5 Gastrointestinal Tract Complications

- 17.6 Acute Inflammatory Syndrome
- 17.8 Administration Instructions
- 17.9 Blood Donation
- 17.10 Semen Donation 17.11 Potential to Impair Driving and Use of Machinery
- \*Sections or subsections omitted from the full prescribing information are not listed.

5.14 Potential Impairment of Ability to Drive or Operate Machinery Mycophenolate mofetil may impact the ability to drive and use machines. Patients should avoid driving or using machines if they experience somnolence, confusion, dizziness, tremor, or hypotension during treatment with mycophenolate mofetil [see Adverse Reactions (6.1)].

## ADVERSE REACTIONS

- The following adverse reactions are discussed in greater detail in other sections of the label:
  Embryofetal Toxicity [see Warnings and Precautions (5.1)]
  Lymphomas and Other Malignancies [see Warnings and Precautions 5.2)]
- Serious Infections [see Warnings and Precautions (5.3)]
- Blood Dyscrasias: Neutropenia, Pure Red Cell Aplasia [see Warnings and Precautions (5.4)] Gastrointestinal Complications [see Warnings and Precautions (5.5)] Acute Inflammatory Syndrome Associated with Mycophenolate Products [see Warnings and Precautions (5.7)]

## 6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. An estimated total of 1557 adult patients received mycophenolate mofetil during pivotal clinical trials in the prevention of acute included in one cardiac study. Patients in all study arms also received cyclosporine and corticosteroids. The data described below primarily derive from five randomized, active-controlled double-blind 12-month trials of mycophenolate mofetil in de novo kidney (3) heart (1) and liver (1) transplant patients [see Clinical Studies (14.1, 14.2, and 14.3)].

## Mycophenolate Mofetil Oral

The incidence of adverse reactions for mycophenolate mofetil was determined in five randomized, comparative, double- blind trials in the prevention of rejection in kidney, heart and liver transplant patients (two active- and one placebo-controlled trials, one active-controlled trial, and one active-controlled trial, respectively) [see Clinical Studies (14.1, 14.2 and 14.3)].

The three *de novo* kidney studies with 12-month duration compared two dose levels of oral mycophenolate mofetil (1 g twice daily and 1.5 g twice daily) with azathioprine (2 studies) or placebo (1 study) when administered in combination with nune<sup>®</sup>) and corticosteroids to prevent acute rejection episodes. One study also included anti-thymocyte cyclosporine (Sand lobulin (ATGAM<sup>®</sup>) induction therapy.

In the *de novo* heart transplantation study with 12-month duration, patients received mycophenolate mofetil 1.5 g twice daily (n=289) or azathioprine 1.5 to 3 mg/kg/day (n=289), in combination with cyclosporine (Sandimmune® or Neoral®) and corticosteroids as maintenance immunosuppressive therapy.

In the de novo liver transplantation study with 12-month duration, patients received mycophenolate mofetil 1 g twice daily intravenously for up to 14 days followed by mycophenolate moteril 1.5 g twice daily orally or azathioprine 1 to 2 mg/kg/day intravenously followed by azathioprine 1 to 2 mg/kg/day orally, in combination with cyclosporine (Neoral®) and corticosteroids as maintenance immunosuppressive therapy. The total number of patients enrolled was 565.

Approximately 53% of the kidney transplant patients, 65% of the heart transplant patients, and 48% of the liver transplant patients were treated for more than 1 year. Adverse reactions reported in  $\ge 20\%$  of patients in the mycophenolate mofetil treatment groups are presented below. The safety data of three kidney transplantation studies are pooled together.

## Table 5 Adverse Reactions in Controlled Studies of De Novo Kidney, Heart or Liver Transplantation Reported in ≥20% of Potients in the Mycophenolate Mefetil Group

10	OVERDOSAGE	Patients in the Mycophenolate Mofetil Group							
11			Kidn	ey Studies		Heart Stu	dy	Liver Stu	dy
12	12.1       Mechanism of Action         12.2       Pharmacodynamics         12.3       Pharmacokinetics         NONCLINICAL TOXICOLOGY         13.1       Carcinogenesis, Mutagenesis, Impairment of Fertility	Adverse drug reaction System Organ Class	Mycophenolate mofetil 2g/day (n=501) or 3g/day (n=490)	AZA 1 to 2 mg/kg/day or 100 to 150 mg/day	Placebo	Mycophenolate mofetil 3g/day	AZA 1.5 to 3 mg/kg/ day	Mycophenolate mofetil 3g/day	AZA 1 to 2 mg/kg/ day
14	CLINICAL STUDIES 14.1 Kidney Transplantation		(n=991)	(n=326)	(n=166)	(n=289)	(n=289)	(n=277)	(n=287)
	14.2       Heart Transplantation         14.3       Liver Transplantation         5       REFERENCES         6       HOW SUPPLIED/STORAGE AND HANDLING		%	%	%	%	%	%	%
15		Infections and infestation	ons			1		<u> </u>	<u> </u>
10		Bacterial infections	39.9	33.7	37.3	-	-	27.4	26.5
17	16.1 Handling and Disposal	Viral infections	_a	-	-	31.1	24.9	-	-
	17.1 Embryofetal Toxicity 17.2 Development of Lymphoma and Other Malignancies	Blood and lymphatic sy	stem disorders						
		Anemia	20.0	23.6	2.4	45.0	47.1	43.0	53.0
		Ecchymosis	-	-	-	20.1	9.7	-	-
	17.4 Blood Dyscrasias	Leukocytosis	-	-	-	42.6	37.4	22.4	21.3
	17.5 Gastrointestinal Tract Complications 17.6 Acute Inflammatory Syndrome	Leukopenia	28.6	24.8	4.2	34.3	43.3	45.8	39.0
	17.7 Immunizations	Thrombocytopenia	-	-	-	24.2	28.0	38.3	42.2
	17.8 Administration Instructions 17.9 Blood Donation	Metabolism and nutrition disorders							
	17.10 Semen Donation	Hypercholesterolemia	-	-	-	46.0	43.9	-	-
	17.11 Potential to Impair Driving and Use of Machinery	Hyperglycemia	-	-	-	48.4	53.3	43.7	48.8
*	*Sections or subsections omitted from the full prescribing information are not listed.	Hyperkalemia	-	-	-	-	-	22.0	23.7
		Hypocalcemia	-	-	-	-	-	30.0	30.0
		Hypokalemia	-	-	-	32.5	26.3	37.2	41.1
		Hypomagnesemia	-	-	-	20.1	14.2	39.0	37.6
		Psychiatric disorders	,,						
		Depression	-	-	-	20.1	15.2	-	-
		Insomnia	-	-	-	43.3	39.8	52.3	47.0
		Nervous system disorde	ers						
5	WARNINGS AND PRECAUTIONS	Dizziness	-	-	-	34.3	33.9	-	-
5.	1 Embryofetal Toxicity	Headache	-	-	-	58.5	55.4	53.8	49.1
	se of MMF during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of ingenital malformations, especially external ear and other facial abnormalities including cleft lip and palate, and anomalies of the	Tremor	-	-	-	26.3	25.6	33.9	35.5
	stal limbs, heart, esophagus, kidney and nervous system. Females of reproductive potential must be made aware of these risks	Cardiac disorders	·	-	-	00.0	01.0	00.0	15.7
	d must be counseled regarding pregnancy prevention and planning. Avoid use of MMF during pregnancy if safer treatment	Tachycardia Vascular disorders	-	-	-	22.8	21.8	22.0	15.7
	tions are available [see Use in Specific Populations (8.1, 8.3)].		27.5	32.2	19.3	78.9	74.0	62.1	59.6
	2 Lymphoma and Other Malignancies tients receiving immunosuppressants, including mycophenolate mofetil, are at increased risk of developing lymphomas and	Hypertension Hypotension	27.5	32.2	- 19.3	34.3	40.1	-	- 59.0
ot	ner malignancies, particularly of the skin [see Adverse Reactions (6.1)]. The risk appears to be related to the intensity and	Respiratory, thoracic a	- A madiaetinal dieo	- rdore	-	34.3	40.1		-
	ration of immunosuppression rather than to the use of any specific agent. For patients with increased risk for skin cancer, posure to sunlight and UV light should be limited by wearing protective clothing and using a broad-spectrum sunscreen with	Cough	-	-	-	40.5	32.2	-	-
	ligh protection factor.	Dyspnea	-	-	-	44.3	44.3	31.0	30.3
	st-transplant lymphoproliferative disorder (PTLD) developed in 0.4% to 1% of patients receiving mycophenolate mofetil (2 g	Pleural effusion	-	-	-	-	-	34.3	35.9
01 R	3 g) with other immunosuppressive agents in controlled clinical trials of kidney, heart and liver transplant patients [see Adverse actions (6.1)]. The majority of PTLD cases appear to be related to Epstein Barr Virus (EBV) infection. The risk of PTLD appears	Gastrointestinal disorde	ers			1			00.0
gr	eatest in those individuals who are EBV seronegative, a population which includes many young children. In pediatric patients,	Abdominal pain	22.4	23.0	11.4	41.9	39.4	62.5	51.2
	other malignancies besides PTLD were observed in clinical trials [see Adverse Reactions (6.1)].	Constipation	-	-	-	43.6	38.8	37.9	38.3
5.	3 Serious Infections		1						

Skin and Appendages	skin benign neoplasm, skin carcinoma				
Psychiatric	confusional state				
Nervous	hypertonia, paresthesia, somnolence				
Musculoskeletal	arthralgia, myasthenia				

The type and frequency of adverse events in a clinical study for prevention of kidney allograft rejection in 100 pediatric patients. 3 months to 18 years of age dosed with mycophenolate mofetil oral suspension 600 mg/m<sup>2</sup> twice daily (up to 1 g twice daily) were generally similar to those observed in adult patients dosed with mycophenolate mofetil capsules at a dose of 1 g twice daily with the exception of abdominal pain, fever, infection, pain, sepsis, diarrhea, vomiting, pharyngitis, respiratory tract infection, mentoesing, lawlaceasic, endengenic, which were observed in a bishes creations in and initia patients dosed. hypertension, leukopenia, and anemia, which were observed in a higher proportion in pediatric patients.

Safety information in pediatric heart transplant or pediatric liver transplant patients treated with mycophenolate mofetil is supported by an open-label study in pediatric liver transplant patients and publications; the type and frequency of the reported adverse reactions are consistent with those observed in pediatric patients following renal transplant and in adults.

Geriatric patients (≥65 years), particularly those who are receiving mycophenolate mofetil as part of a combination immunosuppressive regimen, may be at increased risk of certain infections (including cytomegalovirus [CMV] tissue invasive disease) and possibly gastrointestinal hemorrhage and pulmonary edema, compared to younger individuals [see Warnings and Demotion (C 1) and C 2) are compared to younger individuals (see Warnings and Demotion (C 2) and C 2) and C 2) and C 2) are compared to younger individuals (see Warnings and D 2) and C 2) and C 2) are compared to younger individuals (see Warnings and D 2) and C 2) are compared to younger individuals (see Warnings and D 2) and C 2) are compared to younger individuals (see Warnings and D 2) and C 2) are compared to younger individuals (see Warnings and D 2) are compared to younger individuals (see Warnings and D 2) are compared to younger individuals (see Warnings and D 2) are compared to younger individuals (see Warnings and D 2) are compared to younger individuals (see Warnings and D 2) are compared to younger individuals (see Warnings and D 2) are compared to younger individuals (see Warnings and D 2) are compared to younger individuals (see Warnings and D 2) are compared to younger (see Warnings and D 2) are compared to younger (see Warnings and D 2) are compared to younger (see Warnings and D 2) are compared to younger (see Warnings and D 2) are compared to younger (see Warnings and D 2) are compared to younger (see Warnings and D 2) are compared to younger (see Warnings and D 2) are compared to younger (see Warnings and D 2) are compared to younger (see Warnings and D 2) are compared to younger (see Warnings and D 2) are compared to younger (see Warnings and D 2) are compared to younger (see Warnings and D 2) are compared to younger (see Warnings and D 2) are compared to younger (see Warnings and D 2) are compared to younger (see Warnings and D 2) are compared to younger (see Warnin Precautions (5.3) and Adverse Reactions (6.1)].

Pediatrics

<u>Mycophenolate Mofetil Intravenous</u> The safety profile of mycophenolate mofetil intravenous was determined from a single, double-blind, controlled comparative study of the safety of 2 g/day of intravenous and oral mycophenolate mofetil in kidney transplant patients in the immediate posttransplant period (administered for the first 5 days). The potential venous irritation of mycophenolate mofetil intravenous was evaluated by comparing the adverse reactions attributable to peripheral venous infusion of mycophenolate mofetil intravenous with those observed in the intravenous placebo group; patients in the placebo group received active medication by the oral route. Adverse reactions attributable to peripheral venous infusion were phlebitis and thrombosis, both observed at 4% in patients treated with mycophenolate mofetil intravenous.

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of mycophenolate mofetil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or

- Embryo-Fetal Toxicity: Congenital malformations and spontaneous abortions, mainly in the first trimester, have been reported following exposure to mycophenolate mofetil (MMF) in combination with other immunosuppressants during pregnancy [see Warnings and Precautions (5.1), and Use in Specific Populations (8.1), (8.3)]. Congenital malformations
  - Facial malformations: cleft lip, cleft palate, micrognathia, hypertelorism of the orbits

Table 7 Drug Interactions with Mycophenolate Mofetil that Affect Mycophenolic Acid (MPA) Exposure

mofetil efficacy.

Lansoprazole, pantoprazole

mofetil efficacy.

crobials

- Abnormalities of the ear and eye: abnormally formed or absent external/middle ear, coloboma, microphthalmos Malformations of the fingers: polydactyly, syndactyly, brachydactyly
- Cardiac abnormalities: atrial and ventricular septal defects

7.1 Effect of Other Drugs on Mycophenolate Mofetil

Antacids with Magnesium or Aluminum Hydroxide

Clinical Impact | Conco

Drugs that Interfere with Enterohepatic Recirculation

- Esophageal malformations: esophageal atresia Nervous system malformations: such as spina bifida
- Cardiovascular; Venous thrombosis has been reported in patients treated with mycophenolate mofetil administered
- Digestive: Colitis, pancreatitis

<u>Vascular</u>: Lymphocele

DRUG INTERACTIONS

Proton Pump Inhibitors (PPIs)

Prevention or Management

Drugs Modulating Glucuronidation

Examples

- Hematologic and Lymphatic: Bone marrow failure, cases of pure red cell aplasia (PRCA) and hypogammaglobulinemia have Warnings and Precautions (5.4)].
- Immune: Hypersensitivity, hypogammaglobinemi Infections: Meningitis, infectious endocarditis, tuberculosis, atypical mycobacterial infection, progressive multifocal leukoencephalopathy. BK virus infection, viral reactivation of hepatitis B and hepatitis C, protozoal infections [see Warnings] and Precautions (5.3)1.

Respiratory: Bronchiectasis, interstitial lung disease, fatal pulmonary fibrosis, have been reported rarely and should be considered in the differential diagnosis of pulmonary symptoms ranging from dyspnea to respiratory failure in post-transplant patients receiving mycophenolate mofetil.

Prevention or Management Administer magnesium or aluminum hydroxide containing antacids at least 2h after mycophenolate mofetil administration.

Clinical Impact Concomitant use with PPIs decreases MPA systemic exposure [see Clinical Pharmacology (12.3)], which may reduce mycophenolate mofetil efficacy.

Clinical Impact interfere with enterohepatic recirculation by altering the gastrointestinal flora, can decrease MPA systemic exposure [see Clinical Pharmacology (12.3)], which may reduce mycophenolate

Examples Cyclosporine A, trimethoprim/sulfamethoxazole, bile acid sequestrants (cholestyramine), rifampin as well as aminoglycoside, cephalosporin, fluoroquinolone and penicillin classes of

Clinical Impact Concomitant use with drugs inducing glucuronidation decreases MPA systemic exposure, potentially reducing mycophenolate mofetil efficacy, while use with drugs inhibiting

nisartan (induces glucuronidation); isavuconazole (inhibits glucuronidation

Clinical Impact Concomitant use with calcium free phosphate binders decrease MPA systemic exposure [see Clinical Pharmacology (12.3)], which may reduce mycophenolate mofetil efficacy.

Prevention or Management Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions when these drugs are co-administered with mycophenolate mofetil.

*Prevention or Management* Monitor patients for alterations in efficacy or mycophenolate mofetil related adverse reactions

Prevention or Management Administer calcium free phosphate binders at least 2 hours after mycophenolate mofetil.

when these drugs are co-administered with mycophenolate mofetil.

Concomitant use with an antacid containing magnesium or aluminum hydroxide decreases MPA systemic exposure [see Clinical Pharmacology (12.3)], which may reduce mycophenolate

Monitor patients for alterations in efficacy when PPIs are co- administered with mycophenolate

Concomitant use with drugs that directly interfere with enterohepatic recirculation, or indirectly

glucuronidation increases MPA systemic exposure [see Clinical Pharmacology (12.3)], which may increase the risk of mycophenolate mofetil related adverse reactions.

## therapy.

<u>Mycophenolate Mofetil Capsules</u> Mycophenolate mofetil capsules should not be used interchangeably with mycophenolic acid delayed-release tablets without supervision of a physician with experience in immunosuppressive therapy because the rates of absorption following the

administration of mycophenolate mofetil capsule and mycophenolic acid delayed-release tablets are not equivalent. Mycophenolate mofetil capsules should not be opened or crushed. Patients should avoid inhalation or contact of the skin or mucous membranes with the powder contained in Mycophenolate mofetil capsules. If such contact occurs, they must wash the area of contact thoroughly with soap and water. In case of ocular contact, rinse eyes with plain water.

The initial oral dose of mycophenolate mofetil capsules should be given as soon as possible following kidney, heart or liver transplant. It is recommended that mycophenolate mofetil capsules be administered on an empty stomach. In stable transplant patients, however, mycophenolate mofetil capsules may be administered with food if necessary [see Clinical Pharmacology (12.3)].

Patients should be instructed to take a missed dose as soon as they remember, except if it is closer than 2 hours to the next scheduled dose; in this case, they should continue to take mycophenolate mofetil capsules at the usual times.

## 2.2 Dosage Recommendations for Kidney Transplant Patients

The recommended dosage for adult kidney transplant patients is 1 g orally, twice daily (total daily dose of 2 g).

Pediatrics (3 months and older) Pediatric dosing is based on body surface area (BSA). Pediatric patients with  $BSA \ge 1.25 \text{ m}^2$  may be dosed with capsules as

### Table 1 Pediatric Kidney Transplant: Dosage Using Capsules

	Body Surface Area	Dosage
1.25 m <sup>2</sup> to <1.5 m <sup>2</sup>		Mycophenolate mofetil capsule 750 mg twice daily (1.5 g total daily dose)
	> 1.5 m <sup>2</sup>	Mycophenolate mofetil capsules 1 g twice daily (2 g total daily dose)

### 2.3 Dosage Recommendations for Heart Transplant Patients

<u>Adults</u> The recommended dosage of mycophenolate mofetil capsules for adult heart transplant patients is 1.5 g orally administered twice daily (total daily dose of 3 g).

Pediatrics (3 months and older)

# Pediatric patients with BSA ≥1.25 m<sup>2</sup> may be started on therapy with capsules as follows: Table 2 Pediatric Heart Transplant: Pediatric Starting Dosage Using Capsules

Table 2 Pediatric Heart	Transplant: Pediatric Sta	arting Dosage Using	capsules

Body Surface Area	Starting Dosage*
1.25 m <sup>2</sup> to <1.5 m <sup>2</sup>	Mycophenolate mofetil capsule 750 mg twice daily (1.5 g total daily dose)
≥ 1.5 m <sup>2</sup>	Mycophenolate mofetil capsules 1 g twice daily (2 g total daily dose)

\*Maximum maintenance dose: 3 g total daily.

## 2.4 Dosage Recommendations for Liver Transplant Patients

nded dosage of mycophenolate mofetil capsules for adult liver transplant patients is 1.5 g administered orally twice he recor daily (total daily dose of 3 g).

#### Pediatrics (3 months and older

Pediatric patients with BSA  $\geq$ 1.25 m<sup>2</sup> may be started on therapy with capsules as follows:

Table 3 Pediatric Liver Transplant: Pediatric Starting Dosage Using Capsules

Body Surface Area	Starting Dosage*				
1.25 m <sup>2</sup> to <1.5 m <sup>2</sup>	Mycophenolate mofetil capsule 750 mg twice daily (1.5 g total daily dose)				
≥ 1.5 m <sup>2</sup>	Mycophenolate mofetil capsules 1 g twice daily (2 g total daily dose)				

\*Maximum maintenance dose: 3 g total daily

## 2.5 Dosage Modifications: Patients with Renal Impairment, Neutropenia

Renal Impairment No dosage modifications are needed in kidney transplant patients with delayed graft function postoperatively [see Clinica Pharmacology (12.3)]. In kidney transplant patients with severe chronic impairment of the graft (GFR <25 mL/min/1.73 m<sup>2</sup>), do not administer doses of mycophenolate mofetil capsules greater than 1 g twice a day. These patients should be carefully monitored [see Clinical Pharmacology (12.3)]

### <u>Neutropenia</u>

If neutropenia develops (ANC <1.3 x 10<sup>3</sup>/µL), dosing with mycophenolate mofetil capsules should be interrupted or reduced, appropriate diagnostic tests performed, and the patient managed appropriately [see Warnings and Precautions (5.4) and Adverse Reactions (6.1)].

## 3 DOSAGE FORMS AND STRENGTHS

Mycophenolate mofetil is available in the following dosage form and strength 250 mg mycophenolate mofetil, two-piece hard gelatin capsules, blue/brown colored size '1', hard gelatin Capsules capsules, imprinted with "H" on cap and "M1" on body, filled with white to off white powder

4 CONTRAINDICATIONS

≫-----

Allergic reactions to mycophenolate mofetil capsules have been observed; therefore, Mycophenolate mofetil capsule is contraindicated in patients with a hypersensitivity to mycophenolate mofetil (MMF), mycophenolic acid (MPA) or any component of the drug product.

pressants, including mycophenolate mofetil, are at increased risk of developing bacterial fungal, protozoal and new or reactivated viral infections, including opportunistic infections. The risk increases with the total ive load. These infections may lead to serious outcomes, including hospitalizations and death [see Adverse Reactions (6.1, 6.2)].

Serious viral infections reported include

- Polyomavirus-associated nephropathy (PVAN), especially due to BK virus infection JC virus-associated progressive multifocal leukoencephalopathy (PML), and
- Cytomegalovirus (CMV) infections: CMV seronegative transplant patients who receive an organ from a CMV seropositive donor are at highest risk of CMV viremia and CMV disease.

Viral reactivation in patients infected with Hepatitis B and C COVID-19

Consider dose reduction or discontinuation of mycophenolate mofetil in patients who develop new infections or reactivate viral infections, weighing the risk that reduced immunosuppression represents to the functioning allograft. PVAN, especially due to BK virus infection, is associated with serious outcomes, including deteriorating renal function and renal

graft loss [see Adverse Reactions (6.2)]. Patient monitoring may help detect patients at risk for PVAN. PML, which is sometimes fatal, commonly presents with hemiparesis, apathy, confusion, cognitive deficiencies, and ataxia

[see Adverse Reactions (6.2)]. In immunosuppressed patients, physicians should consider PML in the differential diagnosis in patients reporting neurological symptoms.

The risk of CMV viremia and CMV disease is highest among transplant recipients seronegative for CMV at time of transplant who receive a graft from a CMV seropositive donor. Therapeutic approaches to limiting CMV disease exist and should be routinely provided. Patient monitoring may help detect patients at risk for CMV disease.

/iral reactivation has been reported in patients infected with HBV or HCV. Monitoring infected patients for clinical and laboratory signs of active HBV or HCV infection is recommended.

#### 5.4 Blood Dyscrasias: Neutropenia and Pure Red Cell Aplasia (PRCA)

Severe neutropenia (absolute neutrophil count (ANC) <0.5 x 10<sup>3</sup>/µL) developed in transplant patients receiving mycophenolate mofetil 3 g daily [see Adverse Reactions (6.1)]. Patients receiving mycophenolate mofetil should be monitored for neutropenia. Neutropenia has been observed most frequently in the period from 31 to 180 days post-transplant in patients treated for prevention of kidney, heart and liver rejection. The development of neutropenia may be related to mycophenolate mofetil itself, concomitant medications, viral infections, or a combination of these causes. If neutropenia develops (ANC <1.3  $\times$  10<sup>3</sup>/µL), dosing with mycophenolate mofetil should be interrupted or the dose reduced, appropriate diagnostic tests performed, and the patient managed appropriately [see Dosage and Administration (2.5)].

Patients receiving mycophenolate mofetil should be instructed to report immediately any evidence of infection, unexpected bruising, bleeding or any other manifestation of bone marrow depression.

Consider monitoring with complete blood counts weekly for the first month, twice monthly for the second and third months, and monthly for the remainder of the first year.

Cases of pure red cell aplasia (PRCA) have been reported in patients treated with mycophenolate mofetil in combination with other immunosuppressive agents. In some cases, PRCA was found to be reversible with dose reduction or cessation of mycophenolate mofetil therapy. In transplant patients, however, reduced immunosuppression may place the graft at risk.

#### 5.5 Gastrointestinal Complications

Gastrointestinal bleeding requiring hospitalization, ulceration and perforations were observed in clinical trials. Physicians should be aware of these serious adverse effects particularly when administering mycophenolate mofetil to patients with a gastrointestinal disease.

## 5.6 Patients with Hypoxanthine-Guanine Phosphoribosyl-Transferase Deficiency (HGPRT)

Mycophenolate mofetil is an inosine monophosphate dehydrogenase (IMPDH) inhibitor; therefore it should be avoided in patients with hereditary deficiencies of hypoxanthine-guanine phosphoribosyl-transferase (HGPRT) such as Lesch-Nyhan and Kelley-Seegmiller syndromes because it may cause an exacerbation of disease symptoms characterized by the overproduction and accumulation of uric acid leading to symptoms associated with gout such as acute arthritis, tophi, nephrolithiasis or urolithiasis and renal disease including renal failure.

## 5.7 Acute Inflammatory Syndrome Associated with Mycophenolate Products

Acute inflammatory syndrome (AIS) has been reported with the use of MMF and mycophenolate products, and some cases have resulted in hospitalization. AlS is a paradoxical pro-inflammatory reaction characterized by fever, arthralgias, arthritis, muscle pain and elevated inflammatory markers including, C-reactive protein and erythrocyte sedimentation rate, without evidence of infection or underlying disease recurrence. Symptoms occur within weeks to months of initiation of treatment or a dose increase. After discontinuation, improvement of symptoms and inflammatory markers are usually observed within 24 to 48 hours. Monitor patients for symptoms and laboratory parameters of AIS when starting treatment with mycophenolate products or

when increasing the dosage. Discontinue treatment and consider other treatment alternatives based on the risk and benefit for the patient. 5.8 Immunizations

During treatment with mycophenolate mofetil, the use of live attenuated vaccines should be avoided (e.g., intranasal influenza measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines) and patients should be advised that vaccinations may be less effective. Advise patients to discuss with the physician before seeking any immunizations 5.11 Blood Donation

because their blood or blood products might be administered to a female of reproductive potential or a pregnant woman.

#### 5.13 Effect of Concomitant Medications on Mycophenolic Acid Concentrations

A variety of drugs have potential to alter systemic MPA exposure when co-administered with mycophenolate mofetil. Therefore, determination of MPA concentrations in plasma before and after making any changes to immunosuppressive therapy, or when

Diarrhea	30.4	20.9	13.9	52.6	39.4	51.3	49.8
Dyspepsia	-	-	-	22.1	22.1	22.4	20.9
Nausea	-	-	-	56.1	60.2	54.5	51.2
Vomiting	-	-	-	39.1	34.6	32.9	33.4
Hepatobiliary disorders							
Blood lactate dehydrogenase increased	-	-	-	23.5	18.3	-	-
Hepatic enzyme increased	-	-	-	-	-	24.9	19.2
Skin and subcutaneous	tissues disorders						
Rash	-	-	-	26.0	20.8	-	-
Renal and urinary disor	ders						
Blood creatinine increased	-	-	-	42.2	39.8	-	-
Blood urea increased	-	-	-	36.7	34.3	-	-
General disorders and a	administration site	conditions					
Asthenia	-	-	-	49.1	41.2	35.4	33.8
Edema <sup>b</sup>	21.0	28.2	8.4	67.5	55.7	48.4	47.7

24.8 32.2 9.6 79.2 77.5 74.0 56.4 53.6 52.3 56.1

Indicates that the incidence was below the cutoff value of 20% for inclusion in the table <sup>b:</sup> "Edema" includes peripheral edema, facial edema, scrotal edema. <sup>c:</sup> "Pain" includes musculoskeletal pain (myalgia, neck pain, back pain).

In the three *de novo* kidney studies, patients receiving 2 g/day of mycophenolate mofetil had an overall better safety profile than did patients receiving 3 g/day of mycophenolate mofetil.

Post-transplant lymphoproliferative disease (PTLD, pseudolymphoma) developed in 0.4% to 1% of patients receiving reservation in the provide the server of the occurred in 1.6% to 4.2% of patients, other types of malignancy in 0.7% to 2.1% of patients. Three-year safety data in kidney and heart transplant patients did not reveal any unexpected changes in incidence of malignancy compared to the 1-year data. In pediatric patients, PTLD was observed in 1.35% (2/148) by 12 months post-transplant.

Cytopenias, including leukopenia, anemia, thrombocytopenia and pancytopenia are a known risk associated with mycop and may lead or contribute to the occurrence of infections and hemorrhages [see Warnings and Precautions (5.3)]. Severe neutropenia (ANC  $< 0.5 \times 10^{3}$ /µL) developed in up to 2% of kidney transplant patients, up to 2.8% of heart transplant patients and up to 3.6% of liver transplant patients receiving mycophenolate mofetil 3 g daily [see Warnings and Precautions (5.4) and Dosage and Administration (2.5)].

The most common opportunistic infections in patients receiving mycophenolate mofetil with other immunosuppressants were mucocutaneous candida, CMV viremia/syndrome, and herpes simplex. The proportion of patients with CMV viremia/syndrome was 13.5%. In patients receiving mycophenolate mofetil (2 g or 3 g) in controlled studies for prevention of kidney, heart or liver rejection, fatal infection/sepsis occurred in approximately 2% of kidney and heart patients and in 5% of liver patients [see Warnings and Precautions (5.3)].

The most serious gastrointestinal disorders reported were ulceration and hemorrhage, which are known risks associated with mycophenolate mofetil. Mouth, esophageal, gastric, duodenal, and intestinal ulcers often complicated by hemorrhage, as well as hematemesis, melena, and hemorrhagic forms of gastritis and colitis were commonly reported during the pivotal clinical trials, while the most common gastrointestinal disorders were diarrhea, nausea and voniting. Endoscopic investigation of patients with mycophenolate mofetil-related diarrhea revealed isolated cases of intestinal villous atrophy [see Warnings and Precautions (5.5)1

The following adverse reactions were reported with 3% to <20% incidence in kidney, heart, and liver transplant patients treated with mycophenolate mofetil, in combination with cyclosporine and corticosteroids.

#### Table 6 Adverse Reactions in Controlled Studies of De Novo Kidney, Heart or Liver Transplantation Reported in 3% to <20% of Patients Treated with Mycophenolate Mofetil in Combination with Cyclosporine and Corticosteroids

	System Organ Class	Adverse Reactions
ι, d	Body as a Whole	cellulitis, chills, hernia, malaise
	Infections and Infestations	fungal infections
	Hematologic and Lymphatic	coagulation disorder, ecchymosis, pancytopenia
il	Urogenital	hematuria
	Cardiovascular	hypotension
е	Metabolic and Nutritional	acidosis, alkaline phosphatase increased, hyperlipemia, hypophosphatemia weight loss
9,	Digestive	esophagitis, flatulence, gastritis, gastrointestinal hemorrhage, hepatitis, ileus, nausea and vomiting, stomach ulcer, stomatitis
n	Neoplasm benign, malignant and unspecified	neoplasm

<u>Data</u> nan Data A spectrum of congenital malformations (including multiple malformations in individual newborns) has been reported in 23 to 27% of live births in MMF exposed pregnancies, based on published data from pregnancy registries. Malformations that have been documented include external ear, eye, and other facial abnormalities including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, kidney, and nervous system.

Based on published data from pregnancy registries, the risk of first trimester pregnancy loss has been reported at 45 to 49% following MMF exposure.

## Animal Data

In animal reproductive toxicology studies, there were increased rates of fetal resorptions and malformations in the absence of maternal toxicity. Oral administration of MMF to pregnant rats from Gestational Day 7 to Day 16 produced increased embryofetal lethality and fetal malformations including anophthalmia, agnathia, and hydrocephaly at doses equivalent to 0.015 and 0.01 times the recommended human doses for renal and cardiac transplant patients, respectively, when corrected for BSA. Oral administration of MMF to pregnant rabbits from Gestational Day 7 to Day 19 produced increased embryofetal lethality and fetal malformations included ectopia cordis, ectopic kidneys, diaphragmatic hernia, and umbilical hernia at dose equivalents as low as 0.05 and 0.03 times the recommended human doses for renal and cardiac transplant patients, respectively, when corrected

## 8.2 Lactation

Pregnancy Planning

/our

Tell over way how Esp

<u>Risk Summary</u> There are no data on the presence of mycophenolate in human milk, or the effects on milk production. There are limited data in the National Transplantation Pregnancy Registry on the effects of mycophenolate on a breastfed child [see Data]. Studies in rats treated with MMF have shown mycophenolic acid (MPA) to be present in milk. Because available data are limited, it is not possible to exclude potential risks to a breastfeeding infant.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for mycophenolate mofetil and any potential adverse effects on the breastfed infant from mycophenolate mofetil or from the underlying maternal condition.

Data Limited information is available from the National Transplantation Pregnancy Registry. Of seven infants reported by the National Transplantation Pregnancy Registry to have been breastfed while the mother was taking mycophenolate, all were born at 34 to 40 weeks gestation, and breastfed for up to 14 months. No adverse events were reported.

## 8.3 Females and Males of Reproductive Potential

Females of reproductive potential must be made aware of the increased risk of first trimester pregnancy loss and congenital malformations and must be counseled regarding pregnancy prevention and planning.

as ake Call

you soo and ime.

es as dose same

the ss

kip the doses

way, take

Do Non

your you are ate r

/our your your Jake Do I Do I Do V Do V O O O

oap anes

skin

our

ale) DuS get

tally

For patients who are considering pregnancy, consider alternative immunosuppressants with less potential for embryofetal toxicity whenever possible. Risks and benefits of mycophenolate mofetil should be discussed with the patient.

you get

you

How

Do Do Lake

his bis with (See and vith Tell nd Dd ofeti Ś. ever liver "for can od a fi caps a fi a fi a fi a fi wel Mill size uding birth olate skin **DD** you S e to heart 'gan a st sst est the the / be /ou dici r mycopl will take ause with Ц about and a kidney, the new ( a' fe til) a' fe til) enolate m with your effects, higher ri ome, srase I DS<sup>TM</sup>) Flagyl® and New know 10 to take cers, rescription received a perceives t levels may body can Ì side and I should f them t **not** take /our that • đ st of Do effects. Ę. are who all but , Gil are , pti. iolate etil caps apsules people 's immur side e Keep media hat щщ cap tes. Som ules incisions J pus **possible** and take. new

	Ĩ
	Mycophenols (mye'' koe
Read start	I the Medication Guide that come taking it and each time you refill yo
Medi	Medication Guide does not take the pl condition or treatment.
What	Vhat is the most important informa apsules?
Myc	ipsules can
Incre who durir birth	Increased risk of loss of a pregnancy (n who take mycophenolate mofetil capsule during the first 3 months (first trimeste birth defects
•	f you are a female who can bec
	mycophenolate mofetil capsules. Yo starting mycophenolate mofetil caps
15.	regnancy tests should be repeate o your doctor about the results of
~ 1 @	ou must use acceptable birth con reatment and for 6 weeks after nv time vou choose to avoid se
	Acophenolate mofetil capsules d iills that you take by mouth. Biri
- 0 0 6	niycophenolada moreth dapares, and pills while using mycophenolate mof control. Talk to your doctor about oth mycophenolate mofetil capsules.
• • •	If you are a sexually active male wh are taking mycophenolate mofetil c
• == 0	f you plan to become pregnant,
- = # •	nedicines to prevent rejection may f you become pregnant while t aking myconhenolate mofetil ca
5 P >	loctor may decide that other medi our doctor should report your pre
F	o By phone at 1-800-617-8191 o By visiting the REMS website
Ine purp Increase have a hi doctor if	Life purpose of this registry is to gamer <b>increased risk of getting certain cance</b> Tave a higher risk of getting lymphoma Joctor if you have:
	<ul> <li>unexplained fever, prolonged tir weight loss or lymph node swell</li> </ul>
	sion or
	<ul> <li>a brown or black skin lesic uneven borders, or one part lesion does not look like the oth</li> </ul>
<b>Incre</b> body happ serio	Increased risk of getting serious infec body's immune system and affects yo happen with mycophenolate mofetil caps serious infections can include:
> > •	Viral infections. Certain viruses car your immune system is weak. Viral in
0 0	apsules include: Shingles, other herpes infections tissue and blood infections
0 0	
• • •	a te se s
•	o weakness on one side body
	o you do not care about things usually care about (apathy)
•	I infections. Ye obenolate mofetil t are the possible
• Call	your doctor right away if you have: temperature of 100.5°F or greater
•	
•	unexpected bruising or bleeding

Artwork information						
Customer	Customer Camber Market USA					
Dimensions (mm) 450 x 580 mm Non Printing Colors Die cut						
Pharma Code No.	No. Front-3881 & Back-3882					
Printing Colours (01)	rinting Colours (01) Black					
Others: V:2 Note: Position, Height of the pharma code are tentative, it can be changed based on folding size.						

# Patients should not donate blood during therapy and for at least 6 weeks following discontinuation of mycophenolate mofetil 5.12 Semen Donation Based on animal data, men should not donate semen during therapy and for 90 days following discontinuation of mycophenolate motetil [see Use In Specific Populations (8.3)].

adding or discontinuing concomitant medications, may be appropriate to ensure MPA concentrations remain stable.

Clinical Impact When concomitantly used with mycophenolate mofetil, its metabolite MPAG, may compete with drugs eliminated by renal tubular secretion which may increase plasma concentrations and/or adverse reactions associated with these drugs. Prevention or Management Monitor for drug-related adverse reactions in patients with renal impairment.

77.5

### **Combination Oral Contraceptives**

Examples Calcium Free Phosphate Binders

Examples Sevelame

Table 8 Drug Interactions with Mycophenolate Mofetil that Affect Other Drugs

7.2 Effect of Mycophenolate Mofetil on Other Drugs

Drugs that Undergo Renal Tubular Secretion

Clinical Impact Concomitant use with mycophenolate mofetil decreased the systemic exposure to levonorgestry but did not affect the systemic exposure to ethinylestradiol [see Clinical Pharmacology (12.3)], which may result in reduced combination oral contraceptive effectiveness.

Examples Acyclovir, ganciclovir, probenecid, valacyclovir, valganciclovir

Prevention or Management Use additional barrier contraceptive methods USE IN SPECIFIC POPULATIONS

#### 8.1 Pregnancy

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to mycophenolate during pregnancy and those becoming pregnant within 6 weeks of discontinuing mycophenolate mofetil treatment. To report a pregnancy or obtain information about the registry, visit <u>www.mycophenolateREMS.com</u> or call 1-800-617-8191. Risk Summary

Use of mycophenolate mofetil (MMF) during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of multiple congenital malformations in multiple organ systems [see Human Data]. Oral administration of mycophenolate to rats and rabbits during the period of organogenesis produced congenital malformations and pregnancy loss at doses less than the recommended clinical dose (0.01 to 0.05 times the recommended clinical doses in kidney and heart transplant patients) [see Animal Data].

Consider alternative immunosuppressants with less potential for embryofetal toxicity. Risks and benefits of mycophenolate mofetil should be discussed with the pregnant woman.

The estimated background risk of pregnancy loss and congenital malformations in organ transplant populations is not clear In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

scrapes or i and oozing t are the p about other

cuts, warm **'What** 

are

My and Bei



Table 14 De Novo Kidney Transplantation Studies Cumulative Incidence of Combined Graft Loss or Patient Death at 12

months			
Study	Mycophenolate mofetil 2 g/day	Mycophenolate mofetil 3 g/day	Control (AZA or Placebo)
USA	8.5%	11.5%	12.2%
Europe/Canada/Australia	11.7%	11.0%	13.6%
Europe	8.5%	10.0%	11.5%

## Pediatrics- De Novo Kidney transplantation PK Study with Long Term Follow-Up

One open-label, safety and pharmacokinetic study of mycophenolate mofetil oral suspension 600 mg/m<sup>2</sup> twice daily (up to 1 g twice daily) in combination with cyclosporine and corticosteroids was performed at centers in the United States (9), Europe (5) and Australia (1) in 100 pediatric patients (3 months to 18 years of age) for the prevention of renal allograft rejection. Mycophenolate motetil was well tolerated in pediatric patients *[see Adverse Reactions (6.1)]*, and the pharmacokinetics profile was similar to that seen in adult patients dosed with 1 g twice daily mycophenolate mofetil capsules [see Clinical Pharmacology (12.3)]. The rate of biopsy-proven rejection was similar across the age groups (3 months to <6 years, 6 years to <12 years, 12 years to 18 years). The overall biopsy-proven rejection rate at 6 months was comparable to adults. The combined incidence of graft loss (5%) and patient death (2%) at 12 months post-transplant was similar to that observed in adult kidney transplant

#### 14.2 Heart Transplantation

A double-blind, randomized, comparative, parallel-group, multicenter study in primary de novo heart transplant recipients was performed at centers in the United States (20), in Canada (1), in Europe (5) and in Australia (2). The total number of patients enrolled (ITT population) was 650; 72 never received study drug and 578 received study drug (Safety Population). Patients vpophenolation made of the motelin 1.5 g twice daily (n=289) or AZA 1.5 to 3 mg/kg/day (n=289), in comination with cyclosporine une® or Neoral®) and corticosteroids as maintenance immunosuppressive therapy. The two primary efficacy endpoints received myo were: (1) the proportion of patients who, after transplantation, had at least one endomyocardial biopsy-proven rejection with hemodynamic compromise, or were re-transplanted or ided, within the first 6 months, and (2) the proportion of patients who died or were re-transplanted during the first 12 months following transplantation. Patients who prematurely discontinued treatment were followed for the occurrence of allograft rejection for up to 6 months and for the occurrence of death for 1 year.

- The analyses of the endpoints showed: Rejection: No difference was established between mycophenolate mofetil and AZA with respect to bionsy-proven rejection
- with hemodynamic compromise. Survival: mycophenolate mofetil was shown to be at least as effective as AZA in preventing death or re-transplantation at 1

vear (see Table 15).

able 15	De Novo Heart	Transplantation	Study Rejection	on at 6 Wonths/D	Jeath or Re-t	ransplantation	atir	ear

	All Patients (ITT)		Treated Patients	
	AZA N = 323	Mycophenolate mofetil N = 327	AZA N = 289	Mycophenolate mofetil N = 289
Biopsy-proven rejection with hemodynamic compromise at 6 months <sup>a</sup>	121 (38%)	120 (37%)	100 (35%)	92 (32%)
Death or re-transplantation at 1 year	49 (15.2%)	42 (12.8%)	33 (11.4%)	18 (6.2%)

odynamic compromise occurred if any of the following criteria were met: pulmonary capillary wedge pressure ≥20 mm or a 25% increase; cardiac index <2.0 L/min/m<sup>2</sup> or a 25% decrease; ejection fraction <30%; pulmonary artery oxygen saturation  $\leq$ 60% or a 25% decrease; presence of new S<sub>3</sub> gallop; fractional shortening was  $\leq$ 20% or a 25% decrease; inotropic support required to manage the clinical condition.

### 14.3 Liver Transplantation

A double-blind, randomized, comparative, parallel-group, multicenter study in primary hepatic transplant recipients was performed at centers in the United States (16), in Canada (2), in Europe (4) and in Australia (1). The total number of patients enrolled was 565. Per protocol, patients received mycophenolate mofetil 1 g twice daily intravenously for up to 14 days followed by mycophenolate moteriil 1.5 g twice daily orally or AZA 1 to 2 mg/kg/day intravenously followed by AZA 1 to 2 mg/kg/day orally, in combination with cyclosporine (Neoral<sup>®</sup>) and corticosteroids as maintenance immunosuppressive therapy. The actual median oral dose of AZA on study was 1.5 mg/kg/day (range of 0.3 to 3.8 mg/kg/day) initially and 1.26 mg/kg/day (range of 0.3 to 3.8 mg/kg/day) at 12 months. The two primary endpoints were: (1) the proportion of patients who experienced, in the first 6 months post-transplantation, one or more episodes of biopsy-proven and treated rejection or death or re-transplantation, and (2) the proportion of patients who experienced graft loss (death or re-transplantation) during the first 12 months post-transplantation Patients who prematurely discontinued treatment were followed for the occurrence of allograft rejection and for the occurrence of graft loss (death or re-transplantation) for 1 year.

In combination with corticosteroids and cyclosporine, mycophenolate mofetil demo onstrated a lower rate of acute rejection at 6 months and a similar rate of death or re-transplantation at 1 year compared to AZA (Table 16).

## Table 16 De Novo Liver Transplantation Study Rejection at 6 Months/Death or Retransplantation at 1 Year

	AZA N = 287	Mycophenolate mofetil N = 278
Biopsy-proven, treated rejection at 6 months (includes death or re- transplantation)	137 (47.7%)	107 (38.5%)
Death or re-transplantation at 1 year	42 (14.6%)	41 (14.7%)

## 15 REFERENCES

"OSHA Hazardous Drugs." OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html

### 16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 Handling and Disposal

Mycophenolate motelli (MMF) has demonstrated teratogenic effects in humans [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]. Mycophenolate mofetil capsules should not be opened or crushed. Avoid inhalation or direct contact with skin or mucous membranes of the powder contained in mycophenolate mofetil capsules [see Dosage and Administration (2.6)]. Follow applicable special handling and disposal procedures

#### Frimethoprim/Sulfamethoxazole: Following single-dose administration of MMF (1.5 g) to 12 healthy male volunteers on 16.2 Mycophenolate Mofetil Capsules 250 mg

Blue/Brown colored size '1', hard gelatin capsules, imprinted with "H" on cap and "M1" on body, filled with white to off white powder. They are supplied as follows

NDC 31722-878-01

#### Bottle of 100 Capsules Bottle of 500 Capsules NDC 31722-878-05

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

## 17 PATIENT COUNSELING INFORMATION

dvise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

17.1 Embryofetal Toxicity

Pregnancy loss and malformations

- Inform females of reproductive potential and pregnant women that use of mycophenolate mofetil during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations Advise that they must use an acceptable form of contraception [see Warnings and Precautions (5.1), Use in Specific opulations (8.1, 8.3)].
- Encourage pregnant women to enroll in the Pregnancy Exposure Registry. This registry monitors pregnancy outcomes in women exposed to mycophenolate [see Use in Specific Populations (8.1)].

## **Contraception**

#### Early (Less than 40 days) 1 a/oral 27.3 1.31 8.16 (±0.76) (n=25) (±4.50) (n=25) (±10.9) (n=25) Farly (Less than 40 days) 1.5 g/oral 1.21 13.5 38.4 (±0.81) (±8.18) (±15.4) (n=27) (n=27) (n=27) Late (Greater than 3 months) 1.5 g/oral 0.90 (±0.24) 24.1 (±12.1) 65.3 (±35.4) (n=23) (n=23) (n=23) Heart transplant Patients (twice daily Dose/Route C<sub>max</sub> (mcg/mL) terdosing Interv T<sub>max</sub> (h) dosing) Time After Transplantation (0 to 12h) mcg•h/mL 1.5 g/oral 43.3 (Day before discharge) (±1.3) (±6.8) (±20.8) n=11 (n=11) `(n=9 Late (Greater than 6 months) 20.0 (±9.4) 1.5 g/oral 1.1 (±0.7) (±20.4) n=52) (n=52)(n=49)Liver transplant Patients (twice daily Dose/Rout C<sub>max</sub> nterdosing Interva T<sub>max</sub> (h) dosing) Time After Transplant (mcg/mL) AUC (0 to 12h) (mcg•h/mL) 4 to 9 days 1 g/iv 1.50 17.0 34.0 (±0.517) (±17.4) (±12.7) (n=22) (n=22) (n=22) Early (5 to 8 days) 1.5 g/oral 1.15 13.1 29.2 (±0.432) (±11.9) (±6.76) (n=20) (n=20) (n=20) Late (Greater than 6 months) 1.5 g/oral 1.54 19.3 49.3 (±0.51) (±14.8) (±11.7) (n=6)(n=6)(n=6)

 $^{a}$  ALC(0 to 12b) values quoted are extrapolated from data from samples collected over 4 hours

In the early post-transplant period (less than 40 days post-transplant), kidney, heart, and liver transplant patients had mean MPA

AUGs approximately 20% to 41% lower and mean C<sub>max</sub> approximately 32% to 44% lower compared to the late transplant period (i.e., 3 to 6 months post-transplant) (non-stationarity in MPA pharmacokinetics).

Mean MPA AUC values following administration of 1 g twice daily intravenous mycophenolate mofetil over 2 hours to kidney transplant patients for 5 days were about 24% higher than those observed after oral administration of a similar dose in the mmediate post-transplant phase.

In liver transplant patients, administration of 1 g twice daily intravenous mycophenolate mofetil followed by 1.5 g twice daily oral ycophenolate mofetil resulted in mean MPA AUC estimates similar to those found in kidney transplant patients adm

### g mycophenolate mofetil twice daily. Effect of Food

Food (27 g fat, 650 calories) had no effect on the extent of absorption (MPA AUC) of MMF when administered at doses of 1.5 g twice daily to kidney transplant patients. However, MPA C<sub>max</sub> was decreased by 40% in the presence of food [see Dosage and Administration (2.1)].

## Distribution

The mean (+SD) apparent volume of distribution of MPA in 12 healthy volunteers was approximately 3.6 (+1.5) L/kg. At clinically relevant concentrations, MPA is 97% bound to plasma albumin. The phenolic glucuronide metabolite of MPA is 97% bound to plasma albumin. The phenolic glucuronide metabolite of MPA is 98% bound to plasma albumin at MPAG concentration ranges that are normally seen in stable kidney transplant patients; however, t higher MPAG concentrations (observed in patients with kidney impairment or delayed kidney graft function), the hinding of All night mirka concentrations (observed in patients with where inpatients of delayed under grant intector), the binding of Markov Ma fractions of blood.

In vitro studies to evaluate the effect of other agents on the binding of MPA to human serum albumin (HSA) or plasma proteins showed that salicylate (at 25 mg/dL with human serum albumin) and MPAG (at  $\geq$  460 mg/mL with plasma proteins) increased the free fraction of MPA. MPA at concentrations as high as 100 mcg/mL had little effect on the binding of warfarin, digoxin or propranolol, but decreased the binding of theophylline from 53% to 45% and phenytoin from 90% to 87%

Mean (+SD) apparent half-life and plasma clearance of MPA are 17.9 (+6.5) hours and 193 (+48) mL/min following oral dministration and 16.6 (±5.8) hours and 177 (±31) mL/min following intravenous adm

The parent drug, MMF, can be measured systemically during the intravenous infusion; however, approximately 5 minutes after

ning metabolites of the 2-hydroxyethyl-morpholino molety are also recovered in the urine following oral administration VF to healthy subjects: N-(2-carboxymethyl)-morpholine, N-(2-hydroxyethyl)-morpholine, and the N-oxide of N-(2-MMF to

nterohepatic recirculation of the drug [see Overdosage (10) and Drug Interaction Studies below]

amounts of MPAG are removed.

## ients with Renal Impairment

The mean (±SD) pharmacokinetic parameters for MPA following the administration of oral MMF given as single doses to nontransplant subjects with renal impairment are presented in Table 11.

observed after oral dosing to volunteers with severe chronic renal impairment (GFR < 25 mL/min/1.73 m<sup>2</sup>) was about 75% higher elative to that observed in healthy volunteers (GFR > 80 mL/min/1.73 m<sup>2</sup>). In addition, the single-dose plasma MPAG AUC was 3-fold to 6-fold higher in volunteers with severe renal impairment than in volunteers with mild renal impairment or healthy volunteers, consistent with the known renal elimination of MPAG. No data are available on the safety of long-term exposure to his level of MPAG

Plasma MPA AUC observed after single-dose (1 g) intravenous dosing to volunteers (n=4) with severe chronic renal impairn

#### ent has not been studied. Patients with Delayed Graft Function or Nonfunction

plant patients without delayed renal graft function. There is a potential for a transient inc ease in the free t

mofetil in nediatric patients after receiving allogeneic kidney transplant (100 patients, 3 months to 18 years of age) [see Dosage and Administration (2.2), Adverse Reactions (6.1), Clinical Pharmacology (12.3), Clinical Studies (14.1)]. Heart Transplant and Liver Transplant Use of mycophenolate mofetil in pediatric heart transplant and liver transplant patients is supported by adequate and well-

controlled studies and pharmacokinetic data in adult heart transplant and liver transplant patients. Additional supportive data include pharmacokinetic data in pediatric kidney transplant and pediatric liver transplant patients (8 liver transplant patients, 9 months to 5 years of age, in an open-label, pharmacokinetic and safety study) and published evidence of clinical efficacy and safety in pediatric heart transplant and pediatric liver transplant patients [see Dosage and Administration (2.3, 2.4), Adverse Reactions (6.1), Clinical Pharmacology (12.3), Clinical Studies (14.1)].

Pregnancy Testing To prevent unplanned exposure during pregnancy, all females of reproductive potential should have a serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL immediately before starting mycophenolate mofetil. Another pregnancy test with the same sensitivity should be done 8 to 10 days later. Repeat pregnancy tests should be performed during routine follow-up visits. Results of all pregnancy tests should be discussed with the patient. In the event of a positive pregnancy test, consider alternative to with these sets the appropriate for embryofetal toxicity whenever possible.

Females of reproductive potential taking mycophenolate mofetil must receive contraceptive counseling and use acceptable contraception (see Table 9 for acceptable contraception methods). Patients must use acceptable birth control during the entire mycophenolate mofetil therapy, and for 6 weeks after stopping mycophenolate mofetil, unless the patient chooses abstinence.

Patients should be aware that mycophenolate mofetil reduces blood levels of the hormones from the oral contraceptive pill and

Table 9 Acceptable Contraception Methods for Females of Reproductive Potential Pick from the following birth control

Intrauterine devices (IUDs)

Patient's partner vasectomy

AND

**Barrier Methods** 

Diaphragm with spermicide

Contraceptive sponge

Male condom

Female condom

AND

Cervical cap with spermicide

Barrier Methods

Male condom

Female condom

choose 1

Tubal sterilization

could theoretically reduce its effectiveness [see Drug Interactions (7.2)].

Hormone Methods

Vaginal ring

Progesterone-only • Injection

Implant

Estrogen and Progesterone

Oral Contraceptive Pil

Transdermal patch

Barrier Methods

Diaphragm with spermicide

Contraceptive sponge

Genotoxic effects have been observed in animal studies at exposures exceeding the human therapeutic exposures by

approximately 1.25 times. Thus, the risk of genotoxic effects on sperm cells cannot be excluded. Based on this potential risk

sexually active male patients and/or their female partners are recommended to use effective contraception during treatment

of the male patient and for at least 90 days after cessation of treatment. Also, based on the potential risk of genotoxic effects, male patients should not donate sperm during treatment with mycophenolate mofetil and for at least 90 days after cessation of

Safety and effectiveness have been established in pediatric patients 3 months and older for the prophylaxis of organ rejection of

plate mofetil in this population is supported by evidence from adequate and well-controlled studies of

treatment [see Use in Special Populations (8.1), Nonclinical Toxicology (13.1), Patient Counseling Information (17.9)].

Use of mycophenolate mofetil in this population is supported by evidence from adequate and well-controlled st mycophenolate mofetil in adults with additional data from one open-label, pharmacokinetic and safety study of mycop

Cervical cap with spermicide

choose 1

choose 1

## 8.5 Geriatric Use

Contraception

Female Patients

options:

OR

OR

Option 3

Male Patients

8.4 Pediatric Use

Kidney Transplant

Option 2

Option 1 Methods to Use Alone

Choose One Hormone

Method AND One Barrier Method

Choose One Barrier Method from each

column (must choose two methods)

allogenic kidney, heart or liver transplants.

Clinical studies of mycophenolate mofetil did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between geriatric and younger patients. In general, dose selection for a geriatric patient should take into consideration the presence of decreased hepatic, renal or cardiac function and of concomitant drug therapies [see Adverse Reactions (6.1), Drug Interactions (7)].

## 8.6 Patients with Renal Impairment

Patients with Kidney Transplant No dosage adjustments are needed in kidney transplant patients experiencing delayed graft function postoperatively but patients should be carefully monitored [see Clinical Pharmacology (12.3)]. In kidney transplant patients with severe chronic impairment of the graft (GFR <25 mL/min/1.73 m<sup>2</sup>), no dose adjustments are necessary; however, doses greater than 1 g administered twice a day should be avoided.

## Patients with Heart and Liver Transplant

No data are available for heart or liver transplant patients with severe chronic renal impairment. Mycophenolate mofetil may be used for heart or liver transplant patients with severe chronic renal impairment if the potential benefits outweigh the potential

### 8.7 Patients with Hepatic Impairment Patients with Kidney Transplant

No dosage adjustments are recommended for kidney transplant patients with severe hepatic parenchymal disease. However, it is not known whether dosage adjustments are needed for hepatic disease with other etiologies [see Clinical Pharmacology (12.3)]. Patients with Heart Transplant

data are available for heart transplant patients with severe hepatic parenchymal disease.

## 10 OVERDOSAGE

Possible signs and symptoms of acute overdose include hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea, vomiting, and dyspepsia

The experience with overdose of mycophenolate mofetil in humans is limited. The reported effects associated with overdose The expensive win overloose on hypotheticate inform in minimas is infined. The expensive freed sassociated with overloose fall within the known safety profile of the drug. The highest dose administered to kidney transplant patients in clinical trials has been 4 g/day. In limited experience with heart and liver transplant patients in clinical trials the highest doses used were 4 g/day or 5 g/day. At doses of 4 g/day or 5 g/day, there appears to be a higher rate, compared to the use of 3 g/day or less, of gastrointestinal intolerance (nausea, vomiting, and/or diarrhea), and occasional hematologic abnormalities, particularly neutropenia [see Warnings and Precautions (5.4)].

## Treatment and Management

MPA and the phenolic glucuronide metabolite of MPA (MPAG) are usually not removed by hemodialysis. However, at high MPAG plasma concentrations (>100 mcg/mL), small amounts of MPAG are removed. By increasing excretion of the drug, MPA can be removed by bile acid sequestrants, such as cholestyramine [see Clinical Pharmacology (12.3)].

## 11 DESCRIPTION

Mycophenolate mofetil, USP is an antimetabolite immunosuppressant. It is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosi

sive agent; inosine monophosphate dehydrogenase (IMPDH) inhibitor

Metabolism

Atabolism to MPA occurs pre-systemically after oral dosing. MPA is metabolized principally by glucuronyl transferase to

form MPAG, which is not pharmacologically active. In vivo, MPAG is converted to MPA during enterohepatic recirculation. The vdroxyethyl)-morpholine.

usually observed 6 to 12 hours post-dose. Bile sequestrants, such as cholestyramine, reduce MPA AUC by interfering with this

legligible amount of drug is excreted as MPA (less than 1% of dose) in the urine. Orally administered radiolabeled MMF resulted n complete recovery of the administered dose, with 93% of the administered dose recovered in the urine and 6% recovered in feces. Most (about 87%) of the administered dose is excreted in the urine as MPAG. At clinically encountered concentrations, MPA and MPAG are usually not removed by hemodialysis. However, at high MPAG plasma concentrations (> 100 mcg/mL), small

## Specific Populations

In a single-dose study, MMF was administered as a capsule or as an intravenous infusion over 40 minutes. Plasma MPA AUC

(GFR < 25 mL/min/1.73 m<sup>2</sup>) was 62.4 mcg•h/mL (±19.3). Multiple dosing of MMF in patients with severe chronic renal

In patients with delayed renal graft function post-transplant, mean MPA AUC(0 to 12h) was comparable to that seen in post-


# the infusion is stopped or after oral administration, MMF concentrations are below the limit of quantitation (0.4 mcg/mL).

Due to the enterohepatic recirculation of MPAG/MPA, secondary peaks in the plasma MPA concentration-time profile are

Excretion

Increased plasma concentrations of MMF metabolites (MPA 50% increase and MPAG about a 3-fold to 6-fold increase) are observed in patients with renal insufficiency [see Specific Populations].

cal name for m mofetil, USP (MMF) is 2-mor ethyl (E)-6-(1.3-dihydro-4-hydroxy-6 methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate. It has a molecular formula of C23H31NO7, a molecular weight of 433.5, and the following structural formula:



Mycophenolate mofetil, USP is a white or almost white crystalline powder. It is freely soluble in acetone; sparingly soluble in ethanol and slightly soluble in water. The apparent partition coefficient in 1-octanol/water (pH 7.4) buffer solution is 238. The pKa values for mycophenolate mofetil are 5.6 for the morpholino group and 8.5 for the phenolic group.

Mycophenolate mofetil, USP is available for oral administration as capsules containing 250 mg of mycophenolate mofetil, USP. Inactive ingredients in mycophenolate mofetil capsules USP, 250 mg include croscarmellose sodium, magnesium stearate, povidone (K-90) and pregelatinized starch.

The capsule shells contain FD&C blue #2, gelatin, iron oxide red, iron oxide yellow, sodium lauryl sulfate and titanium dioxide. The capsules are imprinted with a pharmaceutical grade ink containing black iron oxide, potassium hydroxide, propylene glycol, shellac and strong ammonia solution

### 12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite. MPA is a selective uncompetitive inhibitor of the two isoforms (type I and type II) of inosine monophosphate dehydrogenase (IMPDH) leading to inhibition of the *de novo* pathway of guanosine nucleotide synthesis and blocks DNA synthesis. The mechanism of action of MPA is multifaceted and includes effects on cellular checkpoints responsible for metabolic programming of lymphocytes. MPA shifts transcriptional activities in lymphocytes from a proliferative state to catabolic processes. *In vitro* studies suggest that MPA modulates transcriptional activities in human CD4\* T-lymphocytes by suppressing the Akt/mTOR and STAT5 pathways that are relevant to metabolism and survival, leading to an anergic state of T-cells whereby the cells become less responsive to antigenic stimulation. Additionally, MPA enhanced the expression of negative co-stimulators such as CDZ0, PD-1, CTLA-4, and transcription factor FoxP3 as well as decreased the expression of positive co-stimulators CD27 and CD28.

MPA decreases proliferative responses of T- and B-lymphocytes to both mitogenic and allo-antigenic stim responses, as well as the production of cytokines from lymphocytes and monocytes such as GM-CSF, IFN-Y, IL-17, and TNF-α additionally, MPA prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellula adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection. Overall, the effect of MPA is cytostatic and reversible.

## 12.2 Pharmacodynamics

There is a lack of information regarding the pharmacodynamic effects of MMF

12.3 Pharmacokinetics

<u>Absorption</u>

Following oral and intravenous administration, MMF undergoes complete conversion to MPA, the active metabolite. In 12 healthy volunteers, the mean absolute bioavailability of oral MMF relative to intravenous MMF was 94%. Two 500 mg mycophenolate mofetil tablets have been shown to be bioequivalent to four 250 mg mycophenolate mofetil capsules. Five mL of the 200 mg/mL constituted mycophenolate mofetil oral suspension have been shown to be bioequivalent to four 250 mg capsules

The mean (±SD) pharmacokinetic parameters estimates for MPA following the administration of MMF given as single doses to healthy volunteers, and multiple doses to kidney, heart, and liver transplant patients, are shown in **Table 10**. The area under the plasma-concentration time curve (AUC) for MPA appears to increase in a dose- proportional fashion in kidney transplant patients receiving multiple oral doses of MMF up to a daily dose of 3 g (1.5 g twice daily) (see **Table 10**).

## Table 10 Pharmacokinetic Parameters for MPA [mean (±SD)] Following Administration of MMF to Healthy Volunteers

(Single Dose), and Kidney, Heart, and Liver Transplant Patients (Multiple Doses)					
Healthy Volunteers	Dose/Route	T <sub>max</sub> (h)	C <sub>max</sub> (mcg/mL)	Total AUC (mcg•h/mL)	
Single dose	1 g/oral	0.80 (±0.36) (n=129)	24.5 (±9.5) (n=129)	63.9 (±16.2) (n=117)	
Kidney Transplant Patients (twice daily dosing) Time After Transplantation	Dose/Route	T <sub>max</sub> (h)	C <sub>max</sub> (mcg/mL)	Interdosing Interval AUC (0 to 12h) (mcg•h/mL)	
5 days	1 g/iv	1.58 (±0.46) (n=31)	12.0 (±3.82) (n=31)	40.8 (±11.4) (n=31)	
6 days	1 g/oral	1.33 (±1.05) (n=31)	10.7 (±4.83) (n-31)	32.9 (±15.0) (n-31)	

concentration of plasma MPA in patients with delayed renal graft function. However, dose adjustment does not appear to be necessary in patients with delayed renal graft function. Mean plasma MPAG AUC(0 to 12h) was 2-fold to 3-fold higher than in post-transplant patients without delayed renal graft function [see Dosage and Administration (2.5)]. In eight patients with primary graft non-function following kidney transplantation, plasma concentrations of MPAG accumulated about 6-fold to 8-fold after multiple dosing for 28 days. Accumulation of MPA was about 1-fold to 2-fold.

The pharmacokinetics of MMF are not altered by hemodialysis. Hemodialysis usually does not remove MPA or MPAG. At high concentrations of MPAG (> 100 mcg/mL), hemodialysis removes only small amounts of MPAG. Patients with Hepatic Impairment

The mean (± SD) pharmacokinetic parameters for MPA following the administration of oral MMF given as single doses to nontransplant subjects with hepatic impairment is presented in Table 11.

In a single-dose (1 g oral) study of 18 volunteers with alcoholic cirrhosis and 6 healthy volunteers, hepatic MPA glucuronidation processes appeared to be relatively unaffected by hepatic parenchymal disease when pharmacokinetic parameters of healthy volunteers and alcoholic cirrhosis patients within this study were compared. However, it should be noted that for unexplained reasons, the healthy volunteers in this study and about a 50% lower AUC as compared to healthy volunteers in other studies, thus making comparisons between volunteers with alcoholic cirrhosis and healthy volunteers difficult. In a single-dose (1 g intravenous) study of 6 volunteers with severe hepatic impairment (aminopyrine breath test less than 0.2% of dose) due to Icoholic cirrhosis, MMF was rapidly converted to MPA. MPA AUC was 44.1 mcg•h/mL (±15.5). Table 11 Pharmacokinetic Parameters for MPA [mean (±SD)] Following Single Doses of MMF Capsules in Chronic Renal

and Hepatic Impairment

Pharmacokinetic Parameters for Renal Impairment					
	Dose	T <sub>max</sub> (h)	C <sub>max</sub> (mcg/mL)	AUC (0 to 96h) (mcg•h/mL)	
Healthy Volunteers GFR greater than 80 mL/min/1.73 m <sup>2</sup> (n=6)	1 g	0.75 (±0.27)	25.3 (±7.99)	45.0 (±22.6)	
Mild Renal Impairment GFR 50 to 80 mL/min/1.73 m <sup>2</sup> (n=6)	1 g	0.75 (±0.27)	26.0 (±3.82)	59.9 (±12.9)	
Moderate Renal Impairment GFR 25 to 49 mL/min/1.73 m <sup>2</sup> (n=6)	1 g	0.75 (±0.27)	19.0 (±13.2)	52.9 (±25.5)	
Severe Renal Impairment GFR less than 25 mL/min/1.73 m <sup>2</sup> (n=7)	1 g	1.00 (±0.41)	16.3 (±10.8)	78.6 (±46.4)	

Pharmacokinetic Parameters for Hepatic Impairment						
	Dose	T <sub>max</sub> (h)	C <sub>max</sub> (mcg/mL)	AUC (0 to 48h) (mcg•h/mL)		
Healthy Volunteers (n=6)	1 g	0.63 (±0.14)	24.3 (±5.73)	29.0 (±5.78)		
Alcoholic Cirrhosis (n=18)	1 g	0.85 (±0.58)	22.4 (±10.1)	29.8 (±10.7)		

Pediatric Patients The pharmacokinetic parameters of MPA and MPAG have been evaluated in 55 pediatric patients (ranging from 1 year to 18 years of age) receiving mycophenolate mofetil oral suspension at a dose of 600 mg/m<sup>2</sup> twice daily (up to a maximum of 1 g twice daily) after allogeneic kidney transplantation. The pharmacokinetic data for MPA is provided in **Table 12**.

Table 12 Mean (±SD) Computed Pharmacokinetic Parameters for MPA by Age and Time after Allogeneic Kidney

rranspiantation											
Age Group (n)	Time	Tm	T <sub>max</sub> (h)		T <sub>max</sub> (h)		T <sub>max</sub> (h)		djusted <sup>a</sup> ncg/mL)		ldjusted <sup>a</sup> (mcg•h/mL)
1 to less than 2 yr (6) <sup>d</sup>	Early (Day 7)	3.03	(4.70)	10.3	(5.80)	22.5	(6.66)				
1 to less than 6 yr (17)		1.63	(2.85)	13.2	(7.16)	27.4	(9.54)				
6 to less than 12 yr (16)		0.940	(0.546)	13.1	(6.30)	33.2	(12.1)				
12 to 18 yr (21)		1.16	(0.830)	11.7	(10.7)	26.3	(9.14) <sup>b</sup>				
1 to less than 2 yr (4) <sup>d</sup>	Late (Month 3)	0.725	(0.276)	23.8	(13.4)	47.4	(14.7)				
1 to less than 6 yr (15)		0.989	(0.511)	22.7	(10.1)	49.7	(18.2)				
6 to less than 12 yr (14)		1.21	(0.532)	27.8	(14.3)	61.9	(19.6)				
12 to 18 yr (17)		0.978	(0.484)	17.9	(9.57)	53.6	(20.3) <sup>c</sup>				
1 to less than 2 yr (4) <sup>d</sup>	Late (Month 9)	0.604	(0.208)	25.6	(4.25)	55.8	(11.6)				
1 to less than 6 yr (12)		0.869	(0.479)	30.4	(9.16)	61.0	(10.7)				
6 to less than 12 yr (11)		1.12	(0.462)	29.2	(12.6)	66.8	(21.2)				
12 to 18 yr (14)		1.09	(0.518)	18.1	(7.29)	56.7	(14.0)				

<sup>a</sup> adjusted to a dose of 600 mg/m <sup>2</sup>
<sup>b</sup> n=20
<sup>c</sup> n=16
<sup>d</sup> a subset of 1 to <6 vr

#### 13 1 Carci esis, Mutager nent of Fertility

and ceased within 3 days of discontinuation of antibiotics.

espectively, after administration of MMF alone.

In a 104-week oral carcinogenicity study in mice, MMF in daily doses up to 180 mg/kg was not tumorigenic. The highest dose tested was 0.2 times the recommended clinical dose (2 g/day) in renal transplant patients and 0.15 times the recommended clinical dose (3 g/day) in cardiac transplant patients when corrected for differences in body surface area (BSA). In a 104-week oral carcinogenicity study in rats, MMP in daily doses up to 15 mg/kg was not tumorigenic. The highest loss was 0.035 times the recommended clinical dose in kidney transplant patients and 0.025 times the recommended clinical dose in heart transplant patients when corrected for BSA. While these animal doses were lower than those given to patients, they were maximal in those species and were considered adequate to evaluate the potential for human risk [see Warnings and Precautions (5.2)].

MPA AUC values in pediatric patients similar to those seen in adult kidney transplant patients receiving mycophenolate mofetil

capsules at a dose of 1 g twice daily in the early post-transplant period. There was wide variability in the data. As observed in

adults, early post-transplant MPA AUC values were approximately 45% to 53% lower than those observed in the later post transplant period (>3 months). MPA AUC values were similar in the early and late post-transplant period across the 1 to 18-yea

A comparison of dose-normalized (to 600 mg/m<sup>2</sup>) MPA AUC values in 12 pediatric kidney transplant patients less than 6 years

of age at 9 months post-transplant with those values in 7 pediatric liver transplant patients [median age 17 months (range: 10 to 60 months)] and at 6 months and beyond post-transplant revealed that, at the same dose, there were on average 23% lower AUC

values in the pediatric liver compared to pediatric kidney patients. This is consistent with the need for higher dosing in adult liver

In adult transplant patients administered the same dosage of mycophenolate mofetil, there is similar MPA exposure among

kidney transplant and heart transplant patients. Based on the established similarity in MPA exposure between pediatric kidney

transplant and adult kidney transplant patients at their respective approved doses, it is expected that MPA exposure at the

Data obtained from several studies were pooled to look at any gender-related differences in the pharmacokinetics of MPA (data

were adjusted to 1 g oral dose). Mean (±SD) MPA AUC (0 to 12h) for males (n=79) was 32.0 (±14.5) and for females (n=41) was

36.5 (±18.8) mcg•h/mL while mean (±SD) MPA C<sub>max</sub> was 9.96 (±6.19) in the males and 10.6 (±5.64) mcg/mL in the females

The pharmacokinetics of mycophenolate mofetil and its metabolites have not been found to be altered in geriatric transplant

Coadministration of MMF (1 g) and acyclovir (800 mg) to 12 healthy volunteers resulted in no significant change in MPA AUC and

Absorption of a single dose of MMF (2 g) was decreased when administered to 10 rheumatoid arthritis patients also taking

Maalox<sup>®</sup> TC (10 mL gid). The C<sub>max</sub> and AUC(0 to 24h) for MPA were 33% and 17% lower, respectively, than when MMF was

Coadministration of PPIs (e.g., lansoprazole, pantoprazole) in single doses to healthy volunteers and multiple doses to transplant

patients receiving mycophenolate mofetil has been reported to reduce the exposure to MPA. An approximate reduction of 30 to 70% in the  $C_{max}$  and 25% to 35% in the AUC of MPA has been observed, possibly due to a decrease in MPA solubility at an

wing single-dose administration of 1.5 g MMF to 12 healthy volunteers pretreated with 4 g three times a day of cholestyramine

for 4 days, MPA AUC decreased approximately 40%. This decrease is consistent with interruption of enterohepatic recirculation

Cyclosporine (Sandimmune®) pharmacokinetics (at doses of 275 to 415 mg/day) were unaffected by single and multiple doses

14 days of multiple doses of MMF were 3290 (±822) ng•h/mL and 753 (±161) ng/mL, respectively, compared to 3245 (±1088)

Cyclosporine A interferes with MPA enterohepatic recirculation. In kidney transplant patients, mean MPA exposure (AUC(0 to

12h)) was approximately 30 to 50% greater when MMF was administered without cyclosporine compared with when MMF was

(MRP-2) transporter in the biliary tract, thereby preventing the excretion of MPAG into the bile that would lead to enterohepatic

Concomitant administration of drugs inhibiting glucuronidation of MPA may increase MPA exposure (e.g., increase of MPA AUC

Concomitant administration of telmisartan and mycophenolate mofetil resulted in an approximately 30% decrease in MPA

concentrations. Telmisartan changes MPA's elimination by enhancing PPAR gamma (peroxisome proliferator- activated receptor

Following single-dose administration to 12 stable kidney transplant patients, no pharmacokinetic interaction was observed

between MMF (1.5 g) and intravenous ganciclovir (5 mg/kg). Mean (+SD) ganciclovir AUC and C<sub>max</sub> (n=10) were 54.3 (+19.0) mcg•h/mL and 11.5 (±1.8) mcg/mL, respectively, after coadministration of the two drugs, compared to 51.0 (±17.0) mcg•h/mL

and 10.6 (±2.0) mcg/mL, respectively, after administration of intravenous ganciclovir alone. The mean (±SD) AUC and C<sub>max</sub> of MPA (n=12) after coadministration were 80.9 (±21.6) mcg•h/mL and 27.8 (±13.9) mcg/mL, respectively, compared to values of

A study of coadministration of mycophenolate mofetil (1 g twice daily) and combined oral contraceptives containing

ethinylestradiol (0.02 mg to 0.04 mg) and levonorgestrel (0.05 mg to 0.20 mg), desogestrel (0.15 mg) or gestodene (0.05 mg to 0.10 mg) was conducted in 18 women with psoriasis over 3 consecutive menstrual cycles. Mean serum levels of LH, FSH

and progesterone were not significantly affected. Mean AUC(0 to 24h) was similar for ethinylestradiol and 3-keto desogestre

however, mean levonorgestrel AUC(0 to 24h) significantly decreased by about 15%. There was large inter-patient variability (%CV in the range of 60% to 70%) in the data, especially for ethinylestradiol.

Concomitant administration of sevelamer and MMF in adult and pediatric patients decreased the mean MPA C<sub>max</sub> and AUC (0 to

Antimicrobials eliminating beta-glucuronidase-producing bacteria in the intestine (e.g. aminoglycoside, cephalosporin, fluoroquinolone, and penicillin classes of antimicrobials) may interfere with the MPAG/MPA enterohepatic recirculation thus

bility of MPA was observed. The mean ( $\pm$ SD) AUC and C<sub>max</sub> of MPA after concomitant admi

day 8 of a 10-day course of trimethoprim 160 mg/sulfamethoxazole 800 mg administered twice daily, no effect on the

(±19.8) mcg•h/mL and 34.0 (±6.6) mcg/mL, respectively, compared to 79.2 (±27.9) mcg•h/mL and 34.2 (±10.7) mcg/mL.

Norfloxacin and Metronidazole: Following single-dose administration of MMF (1 g) to 11 healthy volunteers on day 4 of a

S-day course of a combination of norfloxacin and metronidazole, the mean MPA AUC(0 to 48h) was significantly reduced by 33% compared to the administration of MMF alone (p<0.05). The mean (±SD) MPA AUC(0 to 48h) after coadministration

of MMF with norfloxacin or metronidazole separately was 48.3 (±24) mcg-h/mL and 42.7 (±23) mcg-h/mL, respectively,

Ciprofloxacin and Amoxicillin Plus Clavulanic Acid: A total of 64 mycophenolate mofetil -treated kidney transplant recipients received either oral ciprofloxacin 500 mg twice daily or amoxicillin plus clavulanic acid 375 mg three times daily for 7 or at

least 14 days, respectively. Approximately 50% reductions in median trough MPA concentrations (pre-dose) from baseline

mycophenolate mofetil alone) were observed in 3 days following commencement of oral ciprofloxacin or amoxicillin plus

lavulanic acid. These reductions in trough MPA concentrations tended to diminish within 14 days of antimicrobial therapy

Rifampin: In a single heart-lung transplant patient, after correction for dose, a 67% decrease in MPA exposure (AUC(0 to

istered with cyclosporine. This interaction is due to cyclosporine inhibition of multidrug-resistance-associated protein 2

f 1.5 g twice daily of MMF in 10 stable kidney transplant patients. The mean (±SD) AUC(0 to 12h) and C<sub>max</sub> of cyclosp

ecirculation of MPA. This information should be taken into consideration when MMF is used without cyclosporine

amma) expression, which in turn results in an enhanced UGT1A9 expression and glucuronidation activity.

80.3 (±16.4) mcg•h/mL and 30.9 (±11.2) mcg/mL, respectively, after administration of MMF alone.

leading to reduced systemic MPA exposure. Information concerning antibiotics is as follows:

compared with 56.2 (±24) mcg·h/mL after administration of MMF alone.

12h)) has been observed with concomitant administration of MMF and rifampin.

transplant patients compared to kidney transplant patients to achieve the same exposure.

recommended dosage will be similar in pediatric heart transplant and adult heart transplant patients.

which may be due to binding of recirculating MPAG with cholestyramine in the intestine.

Ig•h/mL and 700 (±246) ng/mL, respectively, 1 week before administration of MMF.

(0 to  $\infty$ ) by 35% was observed with concomitant administration of isavuconazole

age range.

Male and Female Patients

Geriatric Patients

Acvclovir

Drug Interaction Studies

These differences are not of clinical significance.

patients when compared to younger transplant patients.

Antacids with Magnesium and Aluminum Hydroxides

dministered alone under fasting conditions.

Proton Pumn Inhihitors (PPIs)

Drugs Affecting Glucuronidation

increased gastric pH

Cholestvramine

Cyclospol

Ganciclovir

Oral Contraceptives

Sevelamer

Antimicrobials

12h) by 36% and 26% respectively.

The genotoxic potential of MMF was determined in five assays. MMF was genotoxic in the mouse lymphoma/thymidine kinase assay and the in vivo mouse micronucleus assay. MMF was not genotoxic in the bacterial mutation assay, the yeast mitotic gene conversion assay or the Chinese hamster ovary cell chromosomal aberration assay.

MMF had no effect on fertility of male rats at oral doses up to 20 mg/kg/day. This dose represents 0.05 times the recommended clinical dose in renal transplant patients and 0.03 times the recommended clinical dose in cardiac transplant patients when corrected for BSA. In a female fertility and reproduction study conducted in rats, oral doses of A.5 mg/kg/day caused malformations (principally of the head and eyes) in the first generation offspring in the absence of maternal toxicity. This dose was 0.01 times the recommended clinical dose in renal transplant patients and 0.005 times the recommended clinical dose in cardiac transplant patients when corrected for BSA. No effects on fertility or reproductive parameters were evident in the dams or in the subsequent generation

### 14 CLINICAL STUDIES 14.1 Kidney Transplantation

Adults

13 NONCLINICAL TOXICOLOGY

The three *de novo* kidney transplantation studies compared two dose levels of oral mycophenolate mofetil (1 g twice daily and 1.5 g twice daily) with azathioprine (2 studies) or placebo (1 study) to prevent acute rejection episodes. One of the two studies with azathioprine (AZA) control arm also included anti-thymocyte globulin (ATGAM®) induction therapy. The geographic location of the investigational sites of these studies are included in Table 13.

In all three de novo kidney transplantation studies, the primary efficacy endpoint was the proportion of patients in each treatment group who experienced treatment failure within the first 6 months after transplantation. Treatment failure was defined as biopsyen acute rejection on treatment or the occurrence of death, graft loss or early termination from the study for any reaso without prior biopsy-proven rejection.

Mycophenolate mofetil, in combination with corticosteroids and cyclosporine, reduced (statistically significant at 0.05 level) the incidence of treatment failure within the first 6 months following transplantation (Table 13). Patients who prematurely discontinued treatment were followed for the occurrence of death or graft loss, and the cumulative incidence of graft loss and patient death combined are summarized in Table 14. Patients who prematurely discontinued treatment were not followed for the occurrence of acute rejection after termination

### Table 13 Treatment Failure in De Novo Kidney Transplantation Studies

USA Study (N=499 patients)	Mycophenolate mofetil 2 g/day (n=167 patients)	Mycophenolate mofetil 3 g/day (n=166 patients)	AZA 1 to 2 mg/kg/day (n=166 patients)
	All 3 groups received anti-thymocyte globulin induction, cyclosporin and corticosteroids		
All treatment failures	31.1%	31.3%	47.6%
Early termination without prior acute rejection	9.6%	12.7%	6.0%
Biopsy-proven rejection episode on treatment	19.8%	17.5%	38.0%
Europe/Canada/ Australia Study (N=503 patients)	Mycophenolate mofetil 2 g/day (n=173 patients)	Mycophenolate mofetil 3 g/day (n=164 patients)	AZA 100 to 150 mg/da (n=166 patients)
	No induction treatment administered; all 3 groups received cyclosporing and corticosteroids.		
All treatment failures	38.2%	34.8%	50.0%
Early termination without prior acute rejection	13.9%	15.2%	10.2%
Biopsy-proven rejection episode on treatment	19.7%	15.9%	35.5%
Europe Study (N=491 patients)	Mycophenolate mofetil 2 g/day (n=165 patients)	Mycophenolate mofetil 3 g/day (n=160 patients)	Placebo (n=166 patients)
	No induction treatment administered; all 3 groups received cyclosporin and corticosteroids.		
All treatment failures	30.3%	38.8%	56.0%
Early termination without prior acute rejection	11.5%	22.5%	7.2%

Biopsy-proven rejection episode on treatment 17.0%

No advantage of mycophenolate mofetil at 12 months with respect to graft loss or patient death (combined) was established (Table 14). Numerically, patients receiving mycophenolate mofetil 2 g/day and 3 g/day experienced a better outcome than controls in all three studies; patients receiving mycophenolate mofetil 2 g/day experienced a better outcome than mycophenolate

mofetil 3 g/day in two of the three studies. Patients in all treatment groups who terminated treatment early were found to have a

13.8%

46.4%

poor outcome with respect to graft loss or patient death at 1 year.

<ul> <li>Man dhaud i andi andi angi who alloge models and alloge and the setting should be andity and an endormality and anging should and sho</li></ul>	
---	--

- Discuss pregnancy testing, pregnancy prevention and planning with females of reproduc Populations (8.3)1.
  - Females of reproductive potential must use an acceptable form of birth control during the entire mycophenolate mofetil therapy and for 6 weeks after stopping mycophenolate mofetil, unless the patient chooses abstinence. Mycophenolate mofetil may reduce effectiveness of oral contraceptives. Use of additional barrier contraceptive methods is recommended [see Use in Specific Populations (8.3)]. For patients who are considering pregnancy, discuss appropriate alternative immunosuppressants with less potential for
  - embryofetal toxicity. Risks and benefits of mycophenolate mofetil should be discussed with the patient. Advise sexually active male patients and/or their partners to use effective contraception during the treatment of the male
  - patient and for at least 90 days after cessation of treatment. This recommendation is based on findings of animal studies [see Use in Specific Populations (8.3), Nonclinical Toxicology (13.1)].

## 17.2 Development of Lymphoma and Other Malignancies

Inform patients that they are at increased risk of developing lymphomas and other malignancies, particularly of the skin, due to immunosuppression [see Warnings and Precautions (5.2)]. Advise patients to limit exposure to sunlight and ultraviolet (UV) light by wearing protective clothing and use of broad-spectrum sunscreen with high protection factor.

#### 17.3 Increased Risk of Serious Infections

rm patients that they are at increased risk of developing a variety of infections due to immunosuppression. Instruct them to contact their physician if they develop any of the signs and symptoms of infection explained in the Medication Guide [see Warnings and Precautions (5.3)].

## 17.4 Blood Dyscrasias

rm patients that they are at increased risk for developing blood adverse effects such as anemia or low white blood cells. Advise patients to immediately contact their healthcare provider if they experience any evidence of infection, unexpected bruising, or bleeding, or any other manifestation of bone marrow suppression [see Warnings and Precautions (5.4)]. 17.5 Gastrointestinal Tract Complications

Inform patients that mycophenolate mofetil can cause gastrointestinal tract complications including bleeding, intestinal perforations, and gastric or duodenal ulcers. Advise the patient to contact their healthcare provider if they have symptoms of gastrointestinal bleeding, or sudden onset or persistent abdominal pain [see Warnings and Precautions (5.5)]. 17.6 Acute Inflammatory Syndrome

nform patients that acute inflammatory reactions have been reported in some patients who received mycophenolate mofetil. ome reactions were severe, requiring hospitalization. Advise patients to contact their physician if they develop fever, joint stiffness, joint pain or muscle pains [see Warnings and Precautions (5.7)].

## 17.7 Immunizations

Inform patients that mycophenolate mofetil can interfere with the usual response to immunizations. Before seeking vaccines on their own, advise patients to discuss first with their physician [see Warnings and Precautions (5.8)]. 17.8 Administration Instructions

- Advise patients not to open mycophenolate mofetil capsules
- Advise patients to avoid inhalation or contact of the skin or mucous membranes with the powder contained in mycophenolate mofetil capsules. If such contact occurs, they must wash the area of contact thoroughly with soap and water. In case of ocular contact, rinse eyes with plain water.
  Advise patients to take a missed dose as soon as they remember, except if it is closer than 2 hours to the next scheduled
  - dose; in this case they should continue to take mycophenolate mofetil capsules at the usual times

## 17.9 Blood Donation

Advise patients not to donate blood during therapy and for at least 6 weeks following discontinuation of mycophenolate mofetil [see Warnings and Precautions (5.11)].

17.10 Semen Donation Advise males of childbearing potential not to donate semen during therapy and for 90 days following discontinuation of

#### mycophenolate mofetil [see Warnings and Precautions (5.12)]. 17.11 Potential to Impair Driving and Use of Machinery

Advise patients that mycophenolate mofetil can affect the ability to drive or operate machines. Patients should avoid driving or operating machines if they experience somnolence, confusion, dizziness, tremor or hypotension during treatment with mycophenolate mofetil [see Warnings and Precautions (5.14)].

# CAMBER

Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854

## BV: HETEROTM

Hetero Labs Limited, Unit V, Polepally, Jadcherla, Mahabubnagar - 509 301, India.

Revised: 07/2024

2071127

\*Does not include death and graft loss as reason for early termination

The mycophenolate mofetil oral suspension dose of 600 mg/m<sup>2</sup> twice daily (up to a maximum of 1 g twice daily) achieved mean ×-----